prikaz prve stranice dokumenta Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study
  Preuzmi
PDF 1.84 MB
Znanstveni rad - Izvorni znanstveni rad
Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study
Clinical Ophthalmology, 16 (2022); 3181-3192. https://doi.org/10.2147/OPTH.S382497
Jandroković, Sonja; Vidas Pauk, Sania; Lešin Gaćina, Dina; Škegro, Ivan; Tomić, Martina; Masnec, Sanja; Kuzman, Tomislav; Kalauz, Miro

Citiranost:
,
Citirajte ovaj rad

Jandroković, S., Vidas Pauk, S., Lešin Gaćina, D., Škegro, I., Tomić, M., Masnec, S. ... Kalauz, M. (2022). Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study. Clinical Ophthalmology, 16., 3181-3192. doi: 10.2147/OPTH.S382497

Jandroković, Sonja, et al. "Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study." Clinical Ophthalmology, vol. 16, 2022, str. 3181-3192. https://doi.org/10.2147/OPTH.S382497

Jandroković, Sonja, Sania Vidas Pauk, Dina Lešin Gaćina, Ivan Škegro, Martina Tomić, Sanja Masnec, Tomislav Kuzman i Miro Kalauz. "Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study." Clinical Ophthalmology 16 (2022): 3181-3192. https://doi.org/10.2147/OPTH.S382497

Jandroković, S., et al. (2022) 'Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study', Clinical Ophthalmology, 16, str. 3181-3192. doi: 10.2147/OPTH.S382497

Jandroković S, Vidas Pauk S, Lešin Gaćina D, Škegro I, Tomić M, Masnec S, i sur.. Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study. Clinical Ophthalmology [Internet]. 28.09.2022. [pristupljeno 13.03.2025.];16:3181-3192. doi: 10.2147/OPTH.S382497

S. Jandroković, et al., "Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study", Clinical Ophthalmology, vol. 16, str. 3181-3192, Rujan 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:866615. [Citirano: 13.03.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:866615
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study
AutorSonja Jandroković
AutorSania Vidas Pauk
AutorDina Lešin Gaćina
AutorIvan Škegro
AutorMartina Tomić
AutorSanja Masnec
AutorTomislav Kuzman
AutorMiro Kalauz
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA OFTALMOLOGIJU I OPTOMETRIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Oftalmologija
Sažetak (engleski)
Purpose: To evaluate the effect of switching from preserved prostaglandin analog-timolol fixed combinations (PG-timolol FCs) to preservative-free latanoprost-timolol FC (PF-LT) on intraocular pressure (IOP), ocular surface health, and tolerability in glaucoma and ocular hypertension (OH) patients with the concurrent ocular surface disease (OSD). Methods: This was a longitudinal, prospective, interventional, real-life study among 42 patients. Up to 3 visits were planned, at baseline, 30, and... Više 90 days to assess efficacy on IOP decrease and local tolerance. The severity of OSD symptoms [Ocular Surface Disease Index (OSDI) questionnaire], subjective drug tolerability [visual analog scale (VAS)], conjunctival hyperemia (McMonnies scale), and tear break-up time (TBUT) were the main parameters assessed. Results: Data from 36 patients were available for statistical analysis. IOP was significantly reduced at day 30 and day 90 compared to baseline (16 vs 14 vs 14 mmHg, p < 0.001). Significant improvement was demonstrated in OSD symptoms, signs, and VAS scores from the baseline to the second and third visits. Median OSDI (27.1 vs 9.6 vs 4.2, p < 0.001), conjunctival hyperemia (2 vs 1 vs 1, p < 0.001), corneal surface staining (p < 0.001), and conjunctival staining scores (p < 0.001), and the percentage of patients with eyelid and periocular hyperemia (61.1 vs 12.5 vs 2.8%, p < 0.001), significantly decreased. TBUT (4 vs 5 vs 6 s, p < 0.001) and VAS score regarding tolerability (5 vs 2 vs 1, p < 0.001) significantly increased. Conclusion: A switch from preserved PG-timolol FCs to PF-LT improved tolerability and optimized IOP control, providing better adherence with greater chances of treatment success. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaClinical Ophthalmology
Brojčani podacivol. 16, str. 3181-3192
e-ISSN1177-5483
DOIhttps://doi.org/10.2147/OPTH.S382497
URN:NBNurn:nbn:hr:105:866615
Datum objave publikacije2022-09-28
URL dokumentahttps://www.dovepress.com/tolerability-in-glaucoma-patients-switched-from-preserved-to-preservat-peer-reviewed-fulltext-article-OPTH
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 3.0 (CC BY-NC 3.0)
Datum i vrijeme pohrane2023-08-24 09:03:47
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.